We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

EG:NYSEEverest Group, Ltd. Analysis

Data as of 2026-05-22 - not real-time

$354.52

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

Everest Group (EG) is trading at $354.52, comfortably above its 20‑day and 50‑day SMAs of $351.48 and $339.40, indicating a short‑term bullish bias. The 200‑day SMA sits at $334.58, further supporting a longer‑term uptrend. Momentum is mixed, with the MACD histogram turning negative and the MACD signal labeled “bearish,” while the RSI of 57.8 suggests the stock is neither overbought nor oversold. Valuation metrics are compelling: a trailing P/E of roughly 7x is less than half the industry average of 16.8x, and the price‑to‑book of 0.92 signals a discount to net asset value. The DCF‑derived fair value of $1,314 dwarfs the current price, implying a potential upside of over 200% even after accounting for a modest 9% analyst‑estimated upside. The dividend of $2.00 per share yields about 2.24% with a low payout ratio of 16%, and the company’s free cash flow of $3.99 B comfortably covers the payout. Balance‑sheet strength is evident in a cash pile of $3.64 B that almost matches total debt of $3.59 B, resulting in a modest debt‑to‑equity of 23.5%. Recent material news includes the board’s declaration of the $2.00 dividend and the definitive agreement to sell its Colombian insurance subsidiary to AIG, which should further improve liquidity and focus the business.
Risk‑adjusted returns appear attractive given a low beta of 0.32 and a 30‑day volatility of 19.6%, placing EG in the low‑beta, moderate‑volatility quadrant. The reinsurance sector carries medium regulatory and geographic risk, but the company’s diversified footprint across the U.S., Europe and other markets mitigates concentration. Currency exposure is limited as most operations and reporting are in USD, keeping currency risk low. Overall, the confluence of undervalued multiples, solid cash generation, sustainable dividend and strategic divestiture support a positive outlook across horizons.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Price above short‑term SMAs
  • Neutral RSI with modest upside potential
  • Strong dividend yield and low payout

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Undervalued valuation multiples vs industry
  • Strategic sale of Colombian operations to AIG
  • Robust free cash flow generation

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • DCF fair value suggests >200% upside
  • Low beta and moderate volatility
  • Sustainable dividend with ample cash coverage

Key Metrics & Analysis

Financial Health

Revenue Growth-4.70%
Profit Margin11.73%
P/E Ratio7.2
ROE13.82%
ROA2.66%
Debt/Equity23.47
P/B Ratio0.9
Op. Cash Flow$2.8B
Free Cash Flow$4.0B
Industry P/E16.8

Technical Analysis

TrendBullish
RSI57.8
Support$334.26
Resistance$361.27
MA 20$351.48
MA 50$339.40
MA 200$334.58
MACDBearish
VolumeStable
Fear & Greed Index91.93

Valuation

Fair Value$1,314.39
Target Price$387.13
Upside/Downside9.20%
GradeUndervalued
TypeValue
Dividend Yield2.24%

Risk Assessment

Beta0.32
Volatility19.62%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.